Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AP1189
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis
Details : The data analysis conducted on the first 26 patients who has completed treatment indicates that AP1189 is safe and well tolerated at the current dose schedule.
Product Name : AP1189
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : AP1189
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AP1189
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BRIEF-Synact Pharma Applies For Patent For Ap1189 Within Covid-19
Details : Company has filed a patent application to the European Patent Office covering the use of AP1189 for the treatment of COVID-19 infection, ARDS and SIRS.
Product Name : AP1189
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2020
Lead Product(s) : AP1189
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
